The previous CFO, Oystein Soug, was appointed as Targovax’s CEO on 2 November 2016.
Erik joins from the nutraceutical company Aker Biomarine Antarctic AS, where he held the position as Director of Product Innovation.
Prior to joining Aker Biomarine, Erik worked for Norwegian cancer biotechnology company Algeta ASA, and also has management consulting experience from the Pharma & Health Care practice of McKinsey & Company.
Erik holds a PhD in Molecular Biology from Aarhus University, Denmark, and the Garvan Institute of Medical Research in Sydney, Australia.
Oystein Soug, CEO of Targovax commented: “We are delighted to announce the appointment of Erik as our new CFO. He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background. Erik’s breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients own immune system to fight cancer.”
